AI assistant
Entrada Therapeutics, Inc. — Director's Dealing 2021
Oct 29, 2021
33674_dirs_2021-10-28_8820e510-30ed-42e8-a159-82a713a03d9b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Entrada Therapeutics, Inc. (TRDA)
CIK: 0001689375
Period of Report: 2021-10-28
Reporting Person: Sethuraman Natarajan (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 144762 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.74 | 2029-03-05 | Common Stock (68312) | Direct | |
| Stock Option (Right to Buy) | $2.10 | 2030-12-16 | Common Stock (10284) | Direct | |
| Stock Option (Right to Buy) | $8.47 | 2031-05-20 | Common Stock (96377) | Direct | |
| Stock Option (Right to Buy) | $12.52 | 2031-08-02 | Common Stock (4146) | Direct |
Footnotes
F1: Consists of (i) 114,006 shares of common stock and (ii) 30,756 shares of restricted common stock issued upon early exercise of stock options.
F2: 25% of the shares subject to this option vested and became exercisable on March 4, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3: 25% of the shares subject to this option shall vest and become exercisable on August 12, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F4: 25% of the shares subject to this option shall vest and become exercisable on March 30, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F5: 25% of the shares subject to this option shall vest and become exercisable on August 2, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.